REVEALED: The Secret to potentially Making Rs 18,870, Rs 9,425 and Rs 7,315 in a Single Day...
Here is the latest financial fact sheet of Dr. Reddys. For more details, see the Dr. Reddys quarterly results and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -0.4 |
No. of shares | m | 165.71 |
% ch week | % | 1.1 |
% ch 1-mth | % | -6.9 |
% ch 12-mth | % | 40.6 |
52 week H/L | Rs | 5,514.7/2,497.6 |
No. of Mths Year Ending |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
5-Yr Chart Click to enlarge
|
---|
DR. REDDYS LAB EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 4,383 | 3,397 | 2,788 | 2,875 | 3,363 | |
Low | Rs | 2,750 | 2,560 | 1,902 | 1,888 | 2,352 | |
Sales per share (Unadj.) | Rs | 912.5 | 856.5 | 860.8 | 930.2 | 1,054.2 | |
Earnings per share (Unadj.) | Rs | 124.9 | 78.0 | 57.1 | 117.4 | 121.9 | |
Diluted earnings per share | Rs | 128.6 | 78.0 | 57.1 | 117.7 | 122.3 | |
Cash flow per share (Unadj.) | Rs | 179.9 | 139.9 | 122.0 | 185.8 | 190.2 | |
Dividends per share (Unadj.) | Rs | 20.00 | 20.00 | 20.00 | 20.00 | 25.00 | |
Adj. dividends per share | Rs | 20.59 | 20.00 | 20.02 | 20.04 | 25.07 | |
Dividend yield (eoy) | % | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | |
Book value per share (Unadj.) | Rs | 736.8 | 739.8 | 757.7 | 844.4 | 938.7 | |
Adj. book value per share | Rs | 758.5 | 740.0 | 758.7 | 846.3 | 941.3 | |
Shares outstanding (eoy) | m | 170.61 | 165.74 | 165.91 | 166.07 | 166.17 | |
Bonus/Rights/Conversions | ESOP | BB | ESOP | ESOP | ESOP | ||
Price / Sales ratio | x | 3.9 | 3.5 | 2.7 | 2.6 | 2.7 | |
Avg P/E ratio | x | 28.6 | 38.2 | 41.1 | 20.3 | 23.4 | |
P/CF ratio (eoy) | x | 19.8 | 21.3 | 19.2 | 12.8 | 15.0 | |
Price / Book Value ratio | x | 4.8 | 4.0 | 3.1 | 2.8 | 3.0 | |
Dividend payout | % | 16.0 | 25.7 | 35.0 | 17.0 | 20.5 | |
Avg Mkt Cap | Rs m | 608,481 | 493,632 | 389,034 | 395,496 | 474,831 | |
No. of employees | `000 | 21.7 | 22.7 | 23.5 | 22.0 | 21.7 | |
Total wages/salary | Rs m | 31,174 | 31,068 | 32,149 | 33,562 | 33,802 | |
Avg. sales/employee | Rs Th | 7,184.6 | 6,259.0 | 6,070.8 | 7,032.8 | 8,091.0 | |
Avg. wages/employee | Rs Th | 1,438.6 | 1,369.8 | 1,366.6 | 1,527.9 | 1,561.3 | |
Avg. net profit/employee | Rs Th | 983.2 | 569.7 | 402.5 | 887.7 | 935.8 |
DR. REDDYS LAB INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 155,683 | 141,961 | 142,810 | 154,482 | 175,170 | |
Other income | Rs m | 2,950 | 1,715 | 1,552 | 3,375 | 6,206 | |
Total revenues | Rs m | 158,633 | 143,676 | 144,362 | 157,857 | 181,376 | |
Gross profit | Rs m | 35,853 | 24,722 | 23,512 | 31,782 | 24,421 | |
Depreciation | Rs m | 9,389 | 10,266 | 10,772 | 11,348 | 11,348 | |
Interest | Rs m | 826 | 634 | 788 | 889 | 983 | |
Profit before tax | Rs m | 28,588 | 15,537 | 13,504 | 22,920 | 18,296 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 229 | 349 | 344 | 438 | 561 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 7,511 | 2,965 | 4,380 | 3,858 | -1,403 | |
Profit after tax | Rs m | 21,306 | 12,921 | 9,468 | 19,500 | 20,260 | |
Gross profit margin | % | 23.0 | 17.4 | 16.5 | 20.6 | 13.9 | |
Effective tax rate | % | 26.3 | 19.1 | 32.4 | 16.8 | -7.7 | |
Net profit margin | % | 13.7 | 9.1 | 6.6 | 12.6 | 11.6 |
DR. REDDYS LAB BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 117,940 | 96,837 | 104,984 | 111,101 | 125,991 | |
Current liabilities | Rs m | 63,471 | 84,199 | 68,938 | 58,973 | 72,141 | |
Net working cap to sales | % | 35.0 | 8.9 | 25.2 | 33.7 | 30.7 | |
Current ratio | x | 1.9 | 1.2 | 1.5 | 1.9 | 1.7 | |
Inventory Days | Days | 60 | 73 | 74 | 79 | 73 | |
Debtors Days | Days | 97 | 98 | 104 | 94 | 105 | |
Net fixed assets | Rs m | 73,352 | 102,552 | 104,385 | 101,245 | 83,854 | |
Share capital | Rs m | 853 | 829 | 830 | 830 | 831 | |
"Free" reserves | Rs m | 124,845 | 121,792 | 124,886 | 139,406 | 155,157 | |
Net worth | Rs m | 125,698 | 122,621 | 125,716 | 140,236 | 155,988 | |
Long term debt | Rs m | 10,685 | 5,449 | 25,089 | 22,000 | 1,304 | |
Total assets | Rs m | 203,841 | 218,165 | 225,443 | 224,656 | 232,253 | |
Interest coverage | x | 35.6 | 25.5 | 18.1 | 26.8 | 19.6 | |
Debt to equity ratio | x | 0.1 | 0 | 0.2 | 0.2 | 0 | |
Sales to assets ratio | x | 0.8 | 0.7 | 0.6 | 0.7 | 0.8 | |
Return on assets | % | 10.9 | 6.2 | 4.5 | 9.1 | 9.1 | |
Return on equity | % | 17.0 | 10.5 | 7.5 | 13.9 | 13.0 | |
Return on capital | % | 21.7 | 12.9 | 9.7 | 14.9 | 12.6 | |
Exports to sales | % | 46.6 | 54.6 | 0 | 0 | 0 | |
Imports to sales | % | 9.0 | 9.4 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 72,618 | 77,520 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 14,050 | 13,274 | 0 | 0 | 0 | |
Fx inflow | Rs m | 75,405 | 81,670 | 72,623 | 88,673 | 84,193 | |
Fx outflow | Rs m | 27,115 | 26,355 | 18,916 | 19,104 | 39,616 | |
Net fx | Rs m | 48,290 | 55,315 | 53,707 | 69,569 | 44,577 |
DR. REDDYS LAB CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 32,626 | 21,444 | 18,030 | 28,704 | 29,841 | |
From Investments | Rs m | -20,394 | -18,404 | -14,883 | -7,727 | -4,923 | |
From Financial Activity | Rs m | -17,001 | -3,692 | -4,440 | -21,326 | -25,159 | |
Net Cashflow | Rs m | -474 | -1,144 | -1,236 | -314 | -266 |
Share Holding
|
Company Information
|
CHM: G. V. Prasad | COMP SEC: Sandeep Poddar | YEAR OF INC: 1984 | BSE CODE: 500124 | FV (Rs): 5 | DIV YIELD (%): 0.6 |
More Pharmaceuticals Company Fact Sheets: PFIZER NEULAND LABS FULFORD INDIA STRIDES PHARMA SCIENCE GLENMARK PHARMA
Compare DR. REDDYS LAB With: PFIZER NEULAND LABS FULFORD INDIA STRIDES PHARMA SCIENCE GLENMARK PHARMA
Compare DR. REDDYS LAB With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian share markets are trading on a mixed note tracking a mixed Wall Street session following a big downturn in tech shares.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
This could be the biggest wealth creator of the decade.
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More